Full Press Release Details
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO
Revenue Momentum and Reduced Cash Burn
JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai
Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused
on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases
and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three
months ended March 31, 2025 .
Three (3) Months of 2025 Financial Summary
As of March 31, 2025, Scinai had cash and cash
equivalents and short-term deposits of $1,018 thousand compared to $1,964 thousand as of March 31, 2024.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)
is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology
(I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting
diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development,
clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development
Company website: www.scinai.com.
Investor Relations - Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan,"
"continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking
statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements
reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and
assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd.
Risks and uncertainties include, but are not limited to; the risk that the Company will otherwise be unable to remain compliant with the
continued listing requirements of Nasdaq; lower than anticipated revenues of Scinai's CDMO business in 2025 and thereafter; failure to
sign agreements with other potential clients of the CDMO business; a delay in the commencement and results of pre-clinical and clinical
studies, including the Phase 1/2a study for psoriasis, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results
of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will
not be successful in expanding its CDMO business or in-license other nanoAbs; the risk that Scinai may not be able to secure additional
capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of nanoAbs will not be met or that Scinai
will not be successful in bringing the nanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data
for nanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product
opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory
approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; and the risk that drug development involves a lengthy
and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained
under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission
("SEC") on May 7, 2025, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update
any forward-looking statement for any reason.